Stock Update (NYSE:MRK): Panel recommends Merck & Co continue cholesterol drug study

[Reuters] – Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib. The recommendation comes a month after Eli Lilly & . . . → Read More: Stock Update (NYSE:MRK): Panel recommends Merck & Co continue cholesterol drug study Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – Panel recommends Merck & Co continue cholesterol drug study Stock Update (NYSE:MRK): In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing Stock Update (NYSE:LLY): Lilly continues test of HDL cholesterol drug, on panel’s advice